Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition

Jennifer Tang, Hong Shen*, Xiaofeng Zhao, Vinay K. Holenarsipur, T. Thanga Mariappan, Yueping Zhang, Erika Panfen, Jim Zheng, W. Griffith Humphreys, and Yurong Lai*

Drug Metabolism, Gilead Science Inc., Foster City, California (J.T., X.Z., J.Z., Y.L.); Drug Metabolism and Pharmacokinetics Department, Bristol-Myers Squibb Company, Princeton, New Jersey (H.S., Y.Z., E.P., W.G.H.); and Pharmaceutical Candidate Optimization, Biocon Bristol-Myers Squibb R&D Centre (BBRC), Syngene International Ltd., Bangalore, India (V.K.H., T.T.M.)

Received March 29, 2021; accepted September 28, 2021

ABSTRACT

As an expansion investigation of drug-drug interaction (DDI) from previous clinical trials, additional plasma endogenous metabolites were quantitated in the same subjects to further identify the potential biomarkers of organic anion transporter (OAT) 1/3 inhibition. In the single dose, open label, three-phase with fixed order of treatments study, 14 healthy human volunteers orally received 1000 mg probenecid alone, or 40 mg furosemide alone, or 40 mg furosemide at 1 hour after receiving 1000 mg probenecid on days 1, 8, and 15, respectively. Endogenous metabolites including kynurenic acid, xanthurenic acid, indo-3-acetic acid, pantothenic acid, p-cresol sulfate, and bile acids in the plasma were measured by liquid chromatography–tandem mass spectrometry. The Cmax of kynurenic acids was significantly increased about 3.3- and 3.7-fold over the baseline values at predose followed by the treatment of probenecid alone or in combination with furosemide respectively. In comparison with the furosemide-alone group, the Cmax and area under the plasma concentration–time curve (AUC) up to 12 hours of kynurenic acid were significantly increased about 2.4- and 2.5-fold by probenecid alone, and 2.7- and 2.9-fold by probenecid plus furosemide, respectively. The increases in Cmax and AUC of plasma kynurenic acid by probenecid are comparable to the increases of furosemide Cmax and AUC reported previously. Additionally, the plasma concentrations of xanthurenic acid, indo-3-acetic acid, pantothenic acid, and p-cresol sulfate, but not bile acids, were also significantly elevated by probenecid treatments. The magnitude of effect size analysis for known potential endogenous biomarkers demonstrated that kynurenic acid in the plasma offers promise as a superior addition for early DDI assessment involving OAT1/3 inhibition.

SIGNIFICANCE STATEMENT

This article reports that probenecid, an organic anion transporter (OAT) 1 and OAT3 inhibitor, significantly increased the plasma concentrations of kynurenic acid and several uremic acids in human subjects. Of those, the increases of plasma kynurenic acid exposure are comparable to the increases of furosemide by OAT1/3 inhibition. Effect size analysis for known potential endogenous biomarkers revealed that plasma kynurenic acid is a superior addition for early drug-drug interaction assessment involving OAT1/3 inhibition.

Introduction

The kidneys are specialized organs to remove undesirable substances from the body, and renal elimination is the most common route for many exogenous and endogenous compounds. The processes consist of glomerular filtration, tubular secretion, and reabsorption. Although generally glomerular filtration is a passive process, tubular secretion, and in some cases renal reabsorption, are active processes that are accomplished by a variety of renal transporters located on the basolateral and apical membranes of the renal tubular epithelial cells. Renal transporters that are involved in active renal tubular secretion or reabsorption can be disrupted by inhibitor drugs, leading to clinically significant changes of plasma and/or kidney exposure of victim drugs (Morrissey et al., 2013; Nigam et al., 2015; Ivanyuk et al., 2017). Recently it has become clear that renal transporters play important roles in drug clearance and can be the major determinants of drug exposure in the kidney and plasma. To elucidate the impact of transporter functions on the variations of pharmacokinetics and/or pharmacodynamics of a drug, characterizing the role of renal transporters in the drug disposition and elimination is required by regulatory agencies for new molecular entities to understand the potential drug-drug interactions (DDIs). The US Food and Drug Administration recently published the guides to investigate the clinical DDIs for renally cleared drugs (US Food and Drug Administration, 2020).

Renal transporters on proximal tubular cells work in concert to eliminate exogenous and endogenous substrates from the systemic circulation. The basolateral transporters that take up drugs from blood into proximal tubular cells include organic anion transporter (OAT) and organic cation transporter (OCT) subfamilies. Subsequently the apical transporters such
as multidrug and toxin extrusion proteins (MATEs) and ATP-binding cassette transporters can excrete these substrates from the tubular cells into the urine. The basolateral uptake processes often act as the rate-determining step in renal tubular secretion of anionic compounds (Watanabe et al., 2011; Mathialagan et al., 2017). The uptake of positively charged organic cations is mostly mediated by OCT2. For many negatively charged organic substances, the basolateral uptake is mainly attributed by OAT1 and OAT3, and to a minor extent also OAT2 (Sekine et al., 2006). OAT1 and OAT3 share substrate specificities with some exceptions. For example, both OAT1 and OAT3 can transport cyclic nucleotides, corticosteroids, and prostaglandins (Chu et al., 2001; Ahn and Bhattacharya, 2008), whereas OAT3 has a preference of more bulky and lipophilic organic anionic substrates such as glucuronide conjugates (Srimaroeng et al., 2008). Inhibition of OAT1 and OAT3 can reduce the renal clearance of drugs that are eliminated from renal tubular excretion, resulting in increase of plasma exposure (Ivanuk et al., 2017). It is exemplified that probenecid can reduce the basolateral tubular uptake of cidofovir and protect against cidofovir-induced nephrotoxicity, via the inhibition of OAT1 and OAT3 activities (Yin and Wang, 2016). In addition, in the second third of the twentieth century, probenecid was used to prolong the half-life and reduce the dose of expensive penicillin (Gibaldi and Schwartz, 1968). We now know that OAT1 and OAT3 inhibition can result in increases of plasma exposure for a number of widely prescribed anionic drugs such as furosemide, famotidine, and ciprofloxacin (Inotsume et al., 1990; Jaehe et al., 1995; Vree et al., 1995).

To assess the potential risk of renal transporter DDIs, in vitro testing is recommended by regulatory agencies for all drugs whose tubular secretion constitutes at least 25% of the total clearance. A clinical DDI study with a known inhibitor of these transporters is warranted according to the decision trees in the regulatory guidance (US Food and Drug Administration, 2020). Probenecid is recommended as a clinically relevant inhibitor for OATs. As a general practice, these expensive clinical DDI trials are determined by a static mathematical approach that is conservative by design with a high false positive rate in prediction. Thus, identifying a circulating endogenous biomarker to aid the DDI assessment in phase I clinical trials becomes an attractive and cost-effective means of assessing transporter-mediated DDI potential (Chu et al., 2018; Mariappan et al., 2017; Rodrigues et al., 2018; Müller et al., 2018). In fact, the latest US Food and Drug Administration Guidance for Industry on Drug-Drug Interaction Studies suggests that serum/plasma creatinine levels can be an early index of OCT2 and MATE1/2K inhibition by the investigational drugs (US Food and Drug Administration, 2020).

One of the major functions of the kidney is to filter and excrete water-soluble metabolites yielded from many metabolic processes. Kidney failure causes accumulation of uremic toxins including creatinine, cystein sulfate, hippurate, indole acetate, and indoxyl sulfate. OAT1 and 3 transporters are responsible for tubular uptake of the uremic toxins from blood (El-Sheikh et al., 2008). Through metabolomics analysis, we previously reported that plasma pyridoxic acid (PDA) and homovanillic acid (HVA) and another 27 metabolites can be potential markers of OAT1/3 inhibition in monkeys (Shen et al., 2018). A follow-up clinical study showed that PDA is a promising plasma-based marker of OAT1 and 3 inhibition in humans (Shen et al., 2019). However, as PDA is the primary catabolic product of vitamin B6, the plasma exposure of PDA can be varied by the intake of supplements containing vitamin B6 during the study. Hence, the aim of this follow-up investigation was to further analyze the human plasma samples from the same subjects of clinical furosemide-probenecid DDI studies to assess if these endogenous uremic toxins and bile acids can be potential biomarkers of OAT1 and OAT3 inhibition.

### Methods and Materials

Probenecid (Bencid, 500 mg tablets) and Furosemide (Lasix, 40 mg tablets) were obtained from Geno Pharmaceuticals Limited (Gau, India) and Sanofi India Limited, respectively. Kynurenic acid, xanthurenic acid, pantothenic acid, indo-3-acetic acid, bile acids, and Labetalol were purchased from Sigma Aldrich. p-Cresol sulfate was purchased from ApexBio Technology (Houston, TX). GS-A, a small molecule used for an internal standard in the bioanalytical analysis, was synthesized by chemists at Gilead. All other reagents and solvents used for liquid chromatography–tandem mass spectrometry (LC-MS/MS) were of high-performance liquid chromatography grade, unless specified, and were purchased from Sigma-Aldrich Corporation (Bangalore, India, and St. Louis, MO).

**Clinical Study.** As disclosed previously, the trial was an open-label, three-treatment, three-period, single dose crossover clinical study. The study protocol and the informed consent were reviewed and approved by an independent ethics committee. The study met the Syngene Clinical Development standard operating procedures, International Council for Harmonization “Guidance on Good Clinical Practice” (https://www.ich.org/page/efficacy-guidelines), Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-research-involving-human-subjects/), Central Drugs Standard Control Organization guidelines (http://www.cdsco.nic.in/writereaddata/cdsco-guidecoverindustry.pdf), Indian Council of Medical Research guidelines (https://ethics.nedirindia.org/ICMR_Ethical_Guidelines.aspx), and other applicable regulatory requirements. The clinical part of the study was conducted at one clinical site at Human Pharmacology Unit, Syngene International Limited Clinical Development, Electronics City, Bangalore, India. Fourteen healthy, male, Indian, adult subjects aged between 18 and 45 years were enrolled, and written informed consent for participation was obtained from the subjects prior to initiation of study procedures. No clinically relevant conditions were identified from the medical history, physical examination, electrocardiography, or chest X-ray. Any clinically relevant laboratory abnormalities in clinical chemistry tests including hepatic and renal biochemistry, hematology tests, or urinalysis were criteria for exclusion. Subjects were asked to not take supplements containing vitamin B6 during the study.

The trial consisted of three periods separated by a 7-day washout period between phases, and the healthy volunteers were housed in the clinical facility 36 hours prior to dosing in phase 1. Volunteers orally received probenecid (1000 mg), furosemide (40 mg), and probenecid (1000 mg) plus furosemide (40 mg) with 240 mL of water in phase 1, 2, and 3, respectively. In phase 3, probenecid was dosed 1 hour prior to furosemide administration. Blood samples were collected into tubes containing dipotassium EDTA anticoagulant and centrifuged (2600g at 4°C for 10 minutes) at predose and postdose at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 12.0, 24.0 hours for each phase. In period 3, post-dose time points started after furosemide administration. Subjects were housed in the clinical facility 36 hours prior to dosing in phase 1 (probenecid alone). Safety and tolerability were assessed by clinical evaluations during the study. Plasma was separated into two aliquots that were stored at −70 ± 10°C until analysis.

**Quantification of Kynurenic Acid, Xanthurenic Acid, Pantothenic Acid, p-Cresol Sulfate, Indole-3-Acetic Acid, and Bile Acids by LC-MS/MS.** Stock solutions (10 mM) of test compounds and internal standards were prepared in DMSO (EMD Millipore Corporation, Burlington, MA). Further dilutions were prepared in 50% acetonitrile in water as needed. Plasma calibration standards were prepared in 4× charcoal stripped pooled human plasma with dipotassium EDTA (BioIVT, Westbury, NY) to obtain 13-point standard curves at concentrations ranging from 1 to 50,000 nM. Similarly, quality control (QC)
samples were prepared in plasma at three levels: 20 nM (low QC), 200 nM or 1000 nM (middle QC), 2500 nM or 10,000 nM (high QC), respectively.

Sample extractions were conducted in 96-well plates using protein precipitation with acetonitrile. In brief, 50 μl of study/standard/QC plasma samples were mixed with 200 μl ice-cold acetonitrile containing 200 nM of Labetalol or GS-A in 96-well plates (Greiner Bio-One, Frickenhausen, Germany). Samples were vortex-mixed and centrifuged at 4°C, 3700 rpm for 15 minutes. An aliquot of 100 μl of the supernatant from each well was transferred to a clean 96-well plate and diluted with 200 μl of water. An aliquot of 10 μl was injected to the LC-MS/MS system for analysis.

A CTC PAL autosampler was used as part of a Cohesive (Thermo Scientific, San Jose, CA) LX-2 multiplexed system, and a Dionex Ultimate 3000 UHPLC RS pump was used for elution and separation. Chromatographic separation was achieved by gradient elution on an Acquity C18 BEH, 1.7 μm, 2.1 × 100 mm column (Waters Corporation, Milford, MA) maintained at room temperature. The mobile phase was a mixture of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B).

Mass spectrometric detection were performed on an AB Sciex 5500 QTRAP (Applied Biosystems, Foster City, CA) equipped with an electrospray ionization source. The detection of p-cresol sulfate, indo-3-acetic acid, and bile acids was operated in negative ion mode and multiple reaction monitoring (MRM) transitions in the mass spectrometer, whereas positive ion mode was used for the detection of kynurenic acid, xanthurenic acid, and pantothenic acid. The mass spectrometer settings were as follows: ion spray voltage: 4.5 kV (negative mode) and 5.5 kV (positive mode); temperature: 550°C; MRM transitions and collision energy are listed in Table 1 for all the analytes. All peak integration and data processing were performed using Analyst version 1.6.2 (Applied Biosystems). Concentrations of kynurenic acid, xanthurenic acid, pantothenic acid, creiol sulfate, indo-3-acetic acid, and bile acids in study samples were determined from the weighted (1/x) linear calibration curve obtained by plotting area ratios (analyte-to-internal standard signal) against known concentrations of analyte in calibration standards.

Data Analysis. The pharmacokinetics was analyzed by the noncompartmental analysis in Phoenix WinNonlin software (version 8.2, Certara USA, Inc., Princeton, NJ). The peak concentration (Cmax) values were recorded directly from experimental observations. The area under the plasma concentration–time curve (AUC0–∞) was calculated using the mixed log-linear trapezoidal rule up to 12 hours and the last detectable concentration measured (24 hours) (AUC0–12 and AUC0–24). The relative magnitude of treatment effects of different biomarkers was ranked by standardized effect size (d) by calculating the mean difference of AUC0–12 between the furosemide group and the mean of the probenecid or probenecid plus furosemide groups, and then dividing the result by the pooled standard deviation (eq. 1):

\[
d = \frac{(M_1 - M_2)}{SD_{pooled}}
\]

\[
SD_{pooled} = \sqrt{\frac{SD_1^2 + SD_2^2}{2}}
\]

where M1 and SD1 are the mean of AUC0–12 and S.D. of probenecid or probenecid plus furosemide groups and M2 and SD2 are the mean and S.D. of furosemide treatment.

Statistical differences between treatments were determined using a paired two-tailed Student’s t test. (GraphPad Prism version 7; GraphPad Software, Inc.; San Diego, CA). A P < 0.05 was set as statistically significant.

Results

Drug-Drug Interaction of Probenecid and Furosemide. A total of 14 healthy volunteers were enrolled in this study, and all subjects completed three phases of the study. As reported previously (Shen et al., 2019), the Cmax of probenecid in plasma was 436 ± 157 and 325 ± 41.0 μM in phase 1 (probenecid alone) and phase 3 (probenecid plus furosemide), respectively. The plasma-free concentration-time profiles of probenecid were replotted from the concentration-time profiles that are reported previously (Shen et al., 2019), normalized by the unbound fraction value of probenecid. As shown in Fig. 1A, plasma-free concentrations of probenecid were above the IC50 values of OAT1 and OAT3 for 12 hours (based on the reported geometric mean IC50 value) or 24 hours (based on the reported geometric mean IC50 value) (Shen et al., 2018).

As a result, plasma concentrations of furosemide were significantly increased (Shen et al., 2019), confirming the inhibition of OAT1 and 3 functional activities in human.

Changes in Plasma Concentrations of Kynurenic Acid, Xanthurenic Acid, Pantothenic Acid, P-cresol Sulfate, and Indole-3-Acetic Acid by the Treatment of Probenecid Alone or Probenecid Plus Furosemide. The plasma concentrations of kynurenic acid, xanthurenic acid, pantothenic acid, p-cresol sulfamate, and indole-3-acetic acid were determined before or after receiving probenecid. As shown in Fig. 1B, probenecid alone and in combination with furosemide significantly increased plasma concentrations of kynurenic acid. Although both AUC0–24 and AUC0–12 of kynurenic acid and other tested uremic acids were significantly increased by probenecid (Table 2), the plasma-free concentration of probenecid was greater than the IC50 values of AOT1 and OAT3 inhibition for about 12 hours when the highest IC50

Table 1: MRM transitions and collision energy

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Compound identifier</th>
<th>Q1 mass (m/z)</th>
<th>Q3 mass (m/z)</th>
<th>Collision energy (V)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test compound</td>
<td>Kynurenic acid</td>
<td>190.1</td>
<td>144</td>
<td>26</td>
</tr>
<tr>
<td>Test compound</td>
<td>Xanthurenic acid</td>
<td>206</td>
<td>160</td>
<td>26</td>
</tr>
<tr>
<td>Test compound</td>
<td>Pantothenic acid</td>
<td>230.1</td>
<td>90</td>
<td>20</td>
</tr>
<tr>
<td>Test compound</td>
<td>p-Cresol sulfate</td>
<td>187.3</td>
<td>107</td>
<td>28</td>
</tr>
<tr>
<td>Test compound</td>
<td>Indole-3-acetic acid</td>
<td>174</td>
<td>130</td>
<td>20</td>
</tr>
<tr>
<td>Test compound</td>
<td>TCDCA</td>
<td>498.3</td>
<td>79.9</td>
<td>–95</td>
</tr>
<tr>
<td>Test compound</td>
<td>GDCA</td>
<td>448.3</td>
<td>74</td>
<td>–76</td>
</tr>
<tr>
<td>Test compound</td>
<td>TDCA</td>
<td>498.3</td>
<td>79.9</td>
<td>–76</td>
</tr>
<tr>
<td>Test compound</td>
<td>GCDCA</td>
<td>448.3</td>
<td>74</td>
<td>–76</td>
</tr>
<tr>
<td>Test compound</td>
<td>DCA</td>
<td>391.2</td>
<td>345.4</td>
<td>–46</td>
</tr>
<tr>
<td>Internal standard</td>
<td>Labetalol</td>
<td>329.1</td>
<td>294</td>
<td>27</td>
</tr>
<tr>
<td>Internal standard</td>
<td>Labetalol</td>
<td>327</td>
<td>309.1</td>
<td>–25</td>
</tr>
<tr>
<td>Internal standard</td>
<td>GS-A</td>
<td>431.1</td>
<td>172</td>
<td>44</td>
</tr>
</tbody>
</table>
values reported are used (Fig. 1A). Therefore, the use of AUC_0–12 values is thought to be more appropriate for comparison. Accordingly, the AUC_0–12 of kynurenic acid was increased about 2.5- or 2.9-fold by probenecid or probenecid plus furosemide, respectively, compared with the treatment of furosemide alone. To determine if the increase of plasma exposure of kynurenic acid is associated with the reduction of renal clearance, the concentrations of kynurenic acid in the urine samples were determined. As shown in Supplementary Fig. 1, the renal clearance of kynurenic acid in the subjects received probenecid plus furosemide (phase 3) and furosemide alone (phase 2) were 5.4 ± 1.56 and 10.4 ± 3.02 L/h (mean ± S.D.). The renal clearance of kynurenic acid was reduced about 2-fold by the treatment of probenecid, which confirmed the inhibition of probenecid on the renal excretion of kynurenic acid.

A greater than 2-fold AUC_0–12 increase was also observed in plasma levels of p-cresol sulfate (Fig. 2A) and indole-3-acetic acid (Fig. 2B), after the treatment of probenecid alone or probenecid plus furosemide. The increase of the AUC_0–12 by probenecid was small but statistically significant for xanthurenic acid (1.4-fold) (Fig. 2C) and pantothenic acid (1.2-fold) (Fig. 2D) (Table 2). Similar results were obtained by the treatment of probenecid plus furosemide (Fig. 2; Table 2).

**Effect of Probenecid Alone or Probenecid Plus Furosemide on Plasma Concentration of Bile Acids.** To elucidate the effect of administration of probenecid alone or the coadministration with furosemide on plasma bile acid levels, nonconjugated and glycine- or taurine-conjugated bile acids in the plasma including deoxycholic acid (DCA), taurocholate oxoacid (TCDOA), glycochenodeoxycholic acid (GDCA), glycodeoxycholic acid (GDCDA), and taurodeoxycholic acid (TDCA) were also monitored. Plasma bile acid levels in all treatment groups tended to decline after the administrations up to 4 hours and then elevate after a meal and onwards (Fig. 3). Administration of either probenecid alone or coadministration with furosemide did not significantly alter plasma concentrations of the tested bile acids compared with the pre dose levels or levels observed in the treatment of furosemide alone (Fig. 3).

**The Standardized Effect Size of Known OAT Inhibition Biomarkers.** To select the most sensitive biomarker to predict OAT inhibition DDI, the magnitude of effect size was estimated from the significant changes from the untreated values normalized by the individual variation for known potential endogenous biomarkers, including those previously reported in literature. Although the AUC_0–24 showed comparable changes, the effect size of AUC_0–12 was slightly bigger than that of AUC_0–24 (data not shown). Therefore, the changes of AUC_0–12 values were included in the effect size analysis. As shown in Fig. 4, the standardized effect size of kynurenic acid was about 3-fold higher than xanthurenic and other markers, including HVA, PDA, and 6β-hydroxycortisol that were reported previously (Imamura et al., 2014; Shen et al., 2019). Since the effect size is a quantitative measure of the magnitude of the experimental effect, the largest effect size attributed by kynurenic acid represents the strongest relationship between kynurenic acid exposure and probenecid inhibition. As a result, changes of kynurenic acid AUC_0–12 offer promise as a superior addition for early prediction of DDIs associated with OAT1/3 inhibition.

**Discussion**

To eliminate unpredictable clinical effects, characterization of DDIs with coadministered drugs is an important task for the development of safe drugs for complex diseases that are often treated by multidrug regimens. Conducting clinical DDI studies with investigational new drugs can be time-consuming and expensive and can sometimes cause ethical concerns. Plasma levels of endogenous or nutrient-derived metabolites that can reflect the inhibition of drug metabolizing enzymes or drug transporters in vivo are advantageous for early assessment of DDI potentials in conjunction with the first-in-human tolerability and safety trials without the need to administer probe drugs to healthy volunteers (Imamura et al., 2011; Chu et al., 2018). For example, Tsuura et al. (2016) reported that probenecid can significantly reduce the urinary excretion of taurine and glycochenodeoxycholate sulfate in a dose-dependent manner. Imamura et al. (2014) observed that the plasma exposure of endogenous 6β-hydroxycortisol, an OAT3 substrate, is increased about 2-fold in AUC by probenecid treatment. Most recently, a clinical DDI trial was conducted to confirm that administration of probenecid significantly caused the AUC increase of plasma PDA and HVA (up to 3.2- and 2.1-fold, respectively) (Shen et al., 2019). The AUC increase of PDA is similar to furosemide AUC changes, demonstrating that PDA can be a clinical plasma-based biomarker for DDIs involving OAT1/3 inhibition (Shen et al., 2019). Collectively, DDIs involving OAT inhibition in humans can potentially be assessed by monitoring the plasma concentration of PDA and 6β-hydroxycortisol (Imamura et al., 2014) or renal clearance of taurine and
Table 2: The comparison of plasma exposure of kynurenic acid, pantothenic acid, p-Cresol sulfate, xanthurenic acid, and indole-3-acetic acid by the treatment of probenecid alone or probenecid plus furosemide.

<table>
<thead>
<tr>
<th></th>
<th>Phase 1 (probenecid alone)</th>
<th>Phase 2 (furosemide alone)</th>
<th>Phase 3 (probenecid plus furosemide)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predose (drug-free)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C0 (nM)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cmax (nM)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC0 (nM×h)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fold difference</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rati0 of Cmax/C0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rati0 of AUC0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Kynurenic acid**:
  - C0: 39.7 ± 16.5
  - Cmax: 130 ± 66.3
  - AUC0: 2054 ± 342.9
  - fold difference: 3.3
  - Rati0 of Cmax/C0: 24 AUC0
  - Rati0 of AUC0: 12 Cmax

- **p-Cresol sulfate**:
  - C0: 55.1 ± 22
  - Cmax: 1.4
  - AUC0: 997.8 ± 178.4
  - fold difference: 2.1/2.4
  - Rati0 of Cmax/C0: 451.5 ± 61.9
  - Rati0 of AUC0: 149 ± 48.9

- **Xanthurenic acid**:
  - C0: 1612 ± 126.1
  - Cmax: 2.0
  - AUC0: 2845 ± 407.8
  - fold difference: 2.5/2.9
  - Rati0 of Cmax/C0: NS/1.1
  - Rati0 of AUC0: 1.2/1.2

- **Indole-3-acetic acid**:
  - C0: 2476 ± 2994
  - Cmax: 7370
  - AUC0: 106,929 ± 56,027
  - fold difference: 2.1/2.2
  - Rati0 of Cmax/C0: 52,381 ± 23,404
  - Rati0 of AUC0: 54,014 ± 22,524

- **Pantothenic acid**:
  - C0: 13,481 ± 12,642
  - Cmax: 30,800 ± 29,300
  - AUC0: 559,340 ± 202,509
  - fold difference: 2.3
  - Rati0 of Cmax/C0: 278,561 ± 917,86
  - Rati0 of AUC0: 23,000 ± 24,900

*NS, statistically not significant.*

Predose represents the time zero before administration of probenecid (C0). The values of C0 were averaged from the values at time zero 14 subjects across three phases. Fold changes between phase 1 (probenecid alone) and phase 2 (furosemide alone)/fold changes between phase 3 (probenecid plus furosemide) and phase 2 (furosemide alone).

*P < 0.05.

Tang et al. 1067

Markers. As shown in Table 2, the changes of Cmax over the baseline of probenecid-furosemide DDIs for additional OAT inhibition bio-}

rent investigation reanalyzed the plasma samples from the human trials be associated with in vivo OAT functional actives. Therefore, the cur-

gestted that plasma exposure of these uremic acids and metabolites may
can be affected by diet intake of vitamin B6 and metabolic interconver-
hand the concentrations or the AUC0
tion of probenecid was greater than the IC50 values of OAT1 and

munity of Oat1-gene knockout mice (Wikoff et al., 2011). These results sug-

gdetected in the plasma of monkeys receiving probenecid by untargeted

terd as OAT1/3 inhibition biomarkers. For example, GCDCA-S is

Although the above biomarkers, including the current additions, show statistically significant differences with the fold changes that are
comparable to those in the interacting drugs, statistical significance testing does not reflect the magnitude of the changes or the strength associated with the OAT1 and 3 inhibition. Effect size is a quantitative measurement of the magnitude of the experimental effect. The larger the effect size observed, the stronger the relationship between two variables. Based on the magnitude of effect size estimated from the significant changes of the probenecid untreated group normalized by the interindividual variation for known potential endogenous biomarkers, kynurenic acid appeared to be a promising superior addition for early prediction of DDIs associated with OAT1 and 3 inhibition.

Tryptophan is an essential amino acid and acts as a precursor to redox cofactor NAD⁺ and many biologically active compounds, which play important roles in neuronal and immune function. Tryptophan is enzymatically converted to kynurenine and triggers the kynurenine metabolic pathway. Xanthurenic and kynurenic acid are the key intermediates formed in the tryptophan catabolic pathway and are endogenously produced by several types of cells and tissues (Walczak et al., 2020). Kynurenic acid is a substrate for both human OAT1 and OAT3 (Supplemental Fig. 2), with estimated $K_m$ values of 5.06 and 4.86 μM, respectively (Uwai et al., 2012). Indole-3-acetic acid is a breakdown product by tryptamine deamination associated minor pathways of tryptophan degradation to maintain host-microbe homeostasis (Zhang and Davies, 2016; Anesi et al., 2019). Indole-3-acetic acid is also known as a naturally occurring auxin controlling many important physiologic processes of plants including cell enlargement and division, tissue differentiation, and responses to light and gravity. p-Cresol sulfate, a main circulating uremic toxin, is a sulfate conjugate metabolite of p-cresol that is biosynthesized from dietary tyrosine and phenylalanine by sulfotransferase in the gut (Cao et al., 2000). It is highly protein bound and often elevated in the urine of individuals with progressive multiple sclerosis (Cao et al., 2000). The uptake of p-cresol sulfate in human proximal tubule cells and rat renal cortical slices is saturable and inhibited by probenecid and other OAT inhibitors (Miyamoto et al., 2011). The data suggest that OAT transporters, preferentially OAT3, play a key role in active renal tubular excretion of p-cresol sulfate (Miyamoto et al., 2011). Pantothenic acid, also called vitamin B5, is one of the important water-soluble vitamins for the synthesis of CoA and acyl carrier protein, which is essential for fatty acid metabolism and synthesis. Furthermore, recent research suggests that OAT transporter-centered pathways involve essential metabolites including the tricarboxylic acid cycle and tryptophan metabolites, vitamins, and signaling molecules (Liu et al., 2016). The functional activities of OATs can regulate the plasma levels of these metabolites. In other words, the plasma level of the metabolites can reflect the OAT functional activities. On the other hand, multiple transporters that are expressed both in the kidney and liver can be involved in the elimination of these endogenous metabolites including kynurenic acid. Inhibition of these transporters can have a greater impact on the plasma exposure of these endogenous metabolites (Niemi

**Fig. 3.** The mean plasma concentration–time profiles of DCA (A), TCDCA (B), GCDC (C) GDCA (D), and TDCA (E) after oral administration of probenecid alone (phase 1, open circles), furosemide alone (phase 2, open square), and the coadministration of probenecid plus furosemide (phase 3, open diamonds). The data are expressed as means ± S.D. of 14 healthy volunteers.

**Fig. 4.** Standardized effect size of known potential OAT inhibition biomarkers. The magnitude of effect size was estimated from the significant changes from the untreated values normalized by the interindividual variation of potential plasma endogenous biomarkers 6β-hydroxycortisol (Imamura et al., 2014) (1, study 1; 2, study 2), HVA, and PDA (Shen et al., 2019). The effect size showed is the mean value of the effect size between probenecid alone and furosemide alone and the effect size between probenecid plus furosemide and furosemide alone.
et al., 2003). The transporters that are involved in the transport of uremic acids or the metabolites found in the metabolic networks are not fully understood. For example, it has been reported that kynurenic acid is reportedly also a substrate for both the OATP1B1 and OATP1B3, whereas the transport of indoxyl sulfate involves OATP1B3 (Sato et al., 2014). Probencid can increase the plasma exposure of OATP inhibition biomarker coproporphyrin I (Zhang et al., 2020), likely due to the inhibition of the multi-drug resistance protein 2 on the canalicular membrane (Davenport et al., 2015). In addition, diet intake or the gut microbe can potentially impact the plasma levels of nutrient metabolites, e.g., vitamin B5 and B6 (Liu et al., 2016). As such, although these small acids are not likely eliminated from the liver, further investigation is warranted in understanding the specificity and predictive values of the biomarkers involving OAT transporter inhibition.

In summary, our results demonstrated that probenecid treatment significantly increased the plasma exposure of several uremic acids. The increases in $C_{\text{max}}$ and AUC of plasma kynurenic acid by probenecid are comparable to the increases of furosemide $C_{\text{max}}$ and AUC reported previously. The magnitude of effect sizes for known potential endogenous biomarkers demonstrated that the changes of kynurenic acid $AUC_{0 \rightarrow 12}$ offer promise as a superior addition for early prediction of DDIs associated with OAT1/3 inhibition.

Authorship Contributions

Participated in research design: Shen, Holenarsipur, Mariappan, Humphreys, Lai
Conducted experiments: Tang, Zhao, Zhang, Panfen
Contributed new reagents or analytic tools: Tang, Zhao, Zheng
Performed data analysis: Tang, Shen, Zhao, Zheng, Lai
Wrote or contributed to the writing of the manuscript: Tang, Shen, Zhao, Panfen, Zheng, Humphreys, Lai

References


Address correspondence to: Dr. Hong Shen, Drug Metabolism and Pharmacokinetics Department, Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543. E-mail: hong.shen6@ms.com; or Dr. Yurong.Lai, Gilead Sciences Inc. 333 Lakeside Dr. Foster City, CA 94404. E-mail: Yurong.Lai@gilead.com